Radio-immuno-therapy (RIT)

Radiotherapy (RT) can sensitize tumors to immune checkpoint blockade ICB by promoting a T cell inflamed tumor microenvironment and has shown promising results in pre-clinical models of lung and head and neck cancers. This led to the introduction of Radio-Immuno-Therapy (RIT) as a promising strategy for treatment of cancer. Our lab focuses on identifying mechanisms of response and resistance to RIT. We utilize advanced proteomic and genomic approaches to elucidate new mechanisms and identify potential therapeutic targets.

Recent publications on this topic: